Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S8YL
|
|||
Former ID |
DIB011941
|
|||
Drug Name |
Tomelukast
|
|||
Synonyms |
LY-171883
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Terminated | [1] | |
Company |
Eli Lilly & Co
|
|||
Structure |
Download2D MOL |
|||
Formula |
C16H22N4O3
|
|||
Canonical SMILES |
CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCC2=NNN=N2
|
|||
InChI |
1S/C16H22N4O3/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15/h8-9,22H,3-7,10H2,1-2H3,(H,17,18,19,20)
|
|||
InChIKey |
MWYHLEQJTQJHSS-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 88107-10-2
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:75310
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Leukotriene CysLT1 receptor (CYSLTR1) | Target Info | Modulator | [2], [3] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
IL4 Signaling Pathway | ||||
IL3 Signaling Pathway | ||||
Pathway Interaction Database | Endothelins | |||
Reactome | Leukotriene receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000075) | |||
REF 2 | Effects of chronic treatment with the leukotriene D4 antagonist compound LY171883 on Fischer 344 rats and rhesus monkeys. Fundam Appl Toxicol. 1990 Jan;14(1):123-30. | |||
REF 3 | Effect of the peroxisome proliferator LY171883 on triglyceride accumulation in rats fed a fat-free diet. Biochem Pharmacol. 1991 Sep 12;42(7):1487-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.